A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects

NCT01581242 | Completed Phase 1

• 1 other identifier: BKP-1003
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open-label, three-sequence, three-period, three-treatment clinical trial to investigate the pharmacokinetic drug-drug interaction of Clevudin and Adefovir dipivoxil after oral administration in healthy male subjects.

Conditions

Healthy

Keywords

Clevudine and Adefovir dipivoxil; pharmacokinetic drug drug interaction; oral administration; male subjects

Outcome Measures

Primary Outcomes (2)

• AUClast

  Predose ~24hrs

• Cmax

  Predose~24hrs

Secondary Outcomes (5)

• AUCinf

  Predose~24hrs

• Tmax

  Predose~24hrs

• T1/2

  Predose~24hrs

• CL/F

  Predose~24hrs

• Safety

  Screening, predose, post 24h, Post-study visit

Study Arms (3)

A

EXPERIMENTAL

Drug: Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil

B

EXPERIMENTAL

Drug: Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil

C

EXPERIMENTAL

Drug: Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil

Interventions

Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil DRUG

Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15

A

Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil DRUG

Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;

B

Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil DRUG

Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15

C

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age limit is from 20 to 45 with healthy male subjects in screening
• Weight limit is from 50kg(110.23Ib) to 90kg(198.41Ib) with BMI 18.5-26 (BMI(kg/m2)= weight(kg)/{height(m)}2
• The person who fully understands and listens about this clinical trial, receives written consent to observe the notandum and decides to participate voluntarily

You may not qualify if:

• The person who has past history or serious disease in liver, kidney, nervous system, respiratory system, gastro-intestinal tract system, endocrine system, blood tumor, cardio-vascular system, urinary system, mental system clinically
• The person who has the past history of Gastro-intestinal operation(except simple appendectomy or herniotomy)or Gastro-intestinal system disease (Chron's disease,ulcer,acute and chronic pancreatitis, etc) that can be influenced the absorption of clinical drug
• The person who has the past history of hypersensitivity reaction about the drugs that contain the identical affiliation ingredient or ingredient of Clevudine, Adefovir dipivoxil or others drugs(aspirin, antibiotics etc)or has the significant past history of hypersensitivity reaction clinically
• The person who shows results of the 1.5 times upper limit in screening test of AST(SGOT), ALT(SGPT)
• The person who shows results of the positive HBsAg, HCV Ab,HIV Ab
• The person who has a past history of drug abuse or shows a positive result of drug abuse in urine drug analysis of screening test
• The person who takes medications of some medicine and medical supplies or oriental medicine within 2 weeks before the first administration date', or some OTC drug, vitamin supplements or health functional food within 1week (if only,it's confirmed by the investigator's judgment that they are not affected in pharmacokinetics character and safety evaluation about the clinical drugs)
• The person who participates in other clinical trials within 2 weeks before the first administration date'
• The person who donates plasma pheresis within 1 month before the first administration date, donates whole blood within 2 months before the first administration date or receives a transfusion within a month before the first administration date
• Persistent drinker(over 21 units/week, 1 unit = 10g of pure alcohol) or a drinker who can't stop drinking during hospitalization period
• Smoker who takes a drag over 10 cigarettes per day during the past three months
• The person who was judged unfit for participating in clinical trials by a investigator because of the clinical laboratory test results or other reasons

Sponsors & Collaborators

• Bukwang Pharmaceutical: lead

Study Sites (1)

Clinical Trial Center, Seoul National University Hospital

Seoul, South Korea

Location

MeSH Terms

Interventions

clevudine; adefovir dipivoxil

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 18, 2012
• First Posted: April 20, 2012
• Study Start: April 1, 2012
• Primary Completion: June 1, 2012
• Last Updated: September 18, 2012

Record last verified: 2012-09

Locations

KR (1)